ClinicalTrials.gg
CompletedNCT07263152Updated Aug 13, 2026

QTc Assessment in a Single-Dose Study of Hydronidone Capsules

A Phase 1 interventional study of Hydronidone and Placebo in Hepatic Fibrosis, sponsored by Beijing Continent Pharmaceutical Co, Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by Beijing Continent Pharmaceutical Co, Ltd. (part of GNI Group Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 214 studies in Liver Cirrhosis with a site in China — 65 open to participants now, 73 under way, 4 of them phase 3. Liver Cirrhosis · China.

Enrollment
103rd of 127
48 · median 120
Started
2025
with 18 others
Phase 1
11 of 214
2 open now
Registered
188th of 214
by date
Lead sponsor
6 of 214
Beijing Continent Pharmaceutical Co, Ltd.

Among the 214 studies in Liver Cirrhosis with a site in China, this one is the 103rd largest by enrollment of the 127 interventional ones that give a count, is one of 19 that started in 2025, is one of 11 in phase 1, and was the 188th registered.

Liver Cirrhosis

1,301 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.

Browse Liver Cirrhosis studies →

Open to participants now

65 of the 214 studies in Liver Cirrhosis with a site in China are open now. Recruiting first, the newest first:

60 more — sign in →

All 65 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 214 studies in Liver Cirrhosis with a site in China, or all of them as a file.
02

Study summary

This study was designed with three dose cohorts (A1-A3): a 90 mg cohort, a 270 mg cohort, and a 540 mg cohort. Each cohort enrolled 16 healthy Chinese participants, with 12 receiving the investigational product Hydronidone Capsules and 4 receiving placebo (i.e., matching placebo for Hydronidone Capsules). A total of 48 healthy Chinese subjects were planned for enrollment, and all participants received a single dose under fasting conditions.

03

Conditions studied

  • Hepatic Fibrosis

Browse trials for

Keywords

  • Hydronidone
  • QTc
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1) Participants who were fully informed about this trial before the experiment, understood the content, process and possible adverse events related to the experimental drug, and voluntarily signed the written form.
  • 2) Male or female participants aged 18 to 50 years (including the upper and lower limits) at the time of signing the informed consent form.
  • 3) Male participants with a weight of ≥50.0 kg and female participants with a weight of ≥45.0 kg at the time of screening, and a (BMI) of 19.0 to 26.0 kg/m2, including the boundary values.
  • 4) Participants whose medical history inquiries, laboratory tests and related examinations (vital signs, physical examination, 12-lead , chest X-ray, abdominal color Doppler ultrasound, etc.) were all normal or whose abnormalities were judged by the researcher to have no clinical significance at the time of screening.

Exclusion criteria

Exclusion Criteria:

  • 1) The researcher determines that there are other diseases or medical histories that have clinical significance or may prevent participants from following the research protocol and completing the study, including but not limited to abnormalities in the central nervous system, cardiovascular system, digestive system, respiratory system, urinary system, blood system, immune system, nervous system, endocrine and metabolic system, etc.
  • 2) There is a history of cardiovascular system diseases or risk factors for torsade de pointes (TdP) such as: unexplained syncope; heart failure; myocardial infarction; angina pectoris; atrial fibrillation, atrial flutter, premature ventricular contractions, non-continuous or continuous ventricular tachycardia; severe bradycardia or sick sinus syndrome; hypokalemia or hypomagnesemia; history of interstitial lung disease, pulmonary embolism; history of venous thromboembolism; any personal or family history of cardiac conduction abnormalities; personal or family history of long syndrome (LQTS); or family history of sudden death.
  • 3) During the screening period or baseline period, the 12-lead exceeds the standard: PR > 220ms, QRS > 110ms, HR \< 50 bpm, QTcF ≥ 450 ms; or an abnormal electrocardiogram and the researcher considers it abnormal and of clinical significance (such as, second-degree or higher atrioventricular block, potential bundle branch block, torsade de pointes (TdP), other types of ventricular tachycardia, ventricular fibrillation and ventricular flutter, any T wave changes or any 12-lead electrocardiogram (ECG) results abnormal that affects the QTc interval).
  • 4)Those whose test results for any of the following infectious disease indicators are positive during the screening period: surface antigen, antibody, antigen and antibody, or syphilis spirochete antibody;
  • 5) Those with a history of drug or food allergies, or specific allergies (such as asthma, urticaria, eczema, etc.); or those allergic to hydroxynitone capsules or to the ingredients contained therein;
  • 6) Those who have suffered from a major clinically significant disease within 3 months before the screening or have undergone surgeries that affect drug absorption, distribution, metabolism, excretion (such as gastrointestinal digestive tract, liver and kidney-related surgeries) or other major surgeries, or those who plan to undergo surgery during the study period;
  • 7) Those who have donated blood or lost blood ≥ 400 mL within 3 months before administration, or have received blood transfusion or used blood products within 4 weeks before administration, or those who plan to donate blood during this study period;
  • 8) Those who have participated in any clinical trials as participants and received treatment with trial drugs or devices within 3 months before administration;
  • 9) Those who have taken any prescription drugs, over-the-counter drugs, any vitamin products or herbal medicines within 14 days before administration, or within 5 half-lives (whichever is longer) before administration (based on the longer time period); those who have taken strong inhibitors or strong inducers within 4 weeks before administration, or any drugs known to cause QT/QTc interval prolongation or have a risk of causing torsades de pointes (TdP) (refer to Appendix 10.2); or those who plan to use some chemical drugs, biological products, traditional Chinese medicine or natural medicines that the investigators consider not suitable for taking during the study period;
  • 10) Those who received vaccinations within the past 4 weeks, or those who plan to receive vaccinations during the study period up to 1 month after administration;
  • 11) Those with a history of drug abuse in the past 5 years or within 3 months before screening, or those with positive urine drug abuse screening results at baseline;
  • 12) Those who frequently drink alcohol within 6 months before administration, that is, consuming more than 14 units of alcohol per week (1 unit = 360 mL of beer or 45 mL of 40% alcohol spirits or 150 mL of wine), or those who refuse to stop drinking or consuming any alcoholic products during the trial, or those with positive alcohol breath test results at baseline;
  • 13) Those who smoke more than 5 cigarettes per day 3 months before administration, or those who cannot stop using tobacco products during the trial;
  • 14) Those with a history of motion sickness or needle phobia, or those who cannot tolerate venous catheter puncture;
  • 15) Those with special dietary requirements, those who cannot follow a uniform diet or those who have difficulty swallowing;
  • 16) Those who cannot control their special diet during the trial (including dragon fruit, mango, grapefruit or grapefruit-related citrus fruits (such as lime, pomelo), rambutan, papaya, pomegranate or their products, and/or xanthine diet, caffeinated food or beverages, strong tea, etc.);
  • 17) Those who have taken grapefruit-related citrus fruits (such as lime, pomelo) or their products within 2 weeks before administration, or those who have taken special diets (including dragon fruit, mango or xanthine diet, caffeinated food or beverages, strong tea, etc.) within 48 hours before administration, or those who have engaged in intense exercise, or have other factors affecting drug absorption, distribution, metabolism, and excretion;
  • 18) Pregnant or lactating women, or participants with positive blood pregnancy screening results during the trial;
  • 19) Participants with reproductive capacity who do not agree to use effective methods from the time of signing the form until the end of the trial (see Appendix 3); or those who do not agree to avoid cryopreservation or donation of eggs or sperm during this period;
  • 20) Those who, in the judgment of the investigator, have other reasons that make them unsuitable to participate in this study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Group A1

    Single-dose administration of 90 mg

    Drug: Hydronidone

  • Placebo comparator
    Placebo Group A1

    Single-dose administration of 90 mg

    Drug: Placebo

  • Experimental
    Group A2

    Single-dose administration of 270 mg

    Drug: Hydronidone

  • Placebo comparator
    Placebo Group A2

    Single-dose administration of 270 mg

    Drug: Placebo

  • Experimental
    Group A3

    Single-dose administration of 540 mg

    Drug: Hydronidone

  • Placebo comparator
    Placebo Group A3

    Single-dose administration of 540 mg

    Drug: Placebo

Interventions

  • Experimental group

  • DrugPlacebo

    Placebo group

06

What researchers measure

Primary outcomes

  1. The relationship between plasma drug concentration and placebo-corrected change from baseline in QTc interval (ΔΔQTc) following single-dose administration of Hydroxynidone Capsules

    Time frame: 24 hours after administration

07

Study locations

1 site
  • Beijing Gobroad Hospital
    Beijing, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2025 to primary completion in Feb 2026, 1 month.

Of 32 phase 1 interventional studies under Liver Cirrhosis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 29. This study's 1 month is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2025
First posted
Dec 4, 2025
StartActual
Dec 30, 2025
Primary completionActual
Feb 9, 2026
CompletionActual
Feb 9, 2026
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07263152
Responsible party
Sponsor
First posted
Dec 4, 2025
Start date
Dec 30, 2025
Primary completion
Feb 9, 2026
Completion
Feb 9, 2026
Last update
Aug 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hydronidone

Start the discussion